Health Industry

Latest KFF Health News Stories

KHN’s ‘What the Health?’: Dems Agree to Agree, But Not on What to Agree On

KFF Health News Original

Negotiations on the health parts of President Joe Biden’s domestic agenda are getting serious but have yet to produce a deal every Democrat can support. Meanwhile, the Food and Drug Administration remains without a nominated leader but manages to take the first steps toward approving over-the-counter hearing aids. Joanne Kenen of Politico and Johns Hopkins, Tami Luhby of CNN and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read too.

KHN’s ‘What the Health?’: The Politics of Vaccine Mandates

KFF Health News Original

Like almost everything else associated with the covid-19 pandemic, partisans are taking sides over whether vaccines should be mandated. Meanwhile, Democrats on Capitol Hill are still struggling to find compromise in their effort to expand health insurance and other social programs. Alice Miranda Ollstein of Politico, Jen Haberkorn of the Los Angeles Times and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews best-selling author Beth Macy about her book “Dopesick,” and the new Hulu miniseries based on it.

Hospitals Confront Climate Change as Patients Sick From Floods and Fires Crowd ERs

KFF Health News Original

Patients sickened in heat waves, flooding and wildfire have raised awareness of climate change’s impact on health. Now, some hospitals are building solar panels and cutting waste to reduce their own carbon footprints, with support from a new office at the U.S. Department of Health and Human Services. But the industry is moving slowly.

Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?

KFF Health News Original

Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree — but they are cautious about changing the treatment regimen of patients doing well.